Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Humana Wednesday reported a $796 million fourth quarter loss as the health insurer continued to grapple with high medical costs of its Medicare Advantage health plan members.
Humana (HUM) came out with a quarterly loss of $3.96 per share versus the Zacks Consensus Estimate of a loss of $4.01. This compares to a loss of $2.16 per share a year ago.
HUM heads into Q4 with declining medical membership and rising costs, clouding earnings despite expectations for solid revenue growth.
Evaluate the expected performance of Humana (HUM) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Health insurance company Humana launched Agent Assist, a new artificial intelligence-driven support tool developed with Google Cloud, according to a Tuesday (Feb. 3) press release. The tool is designed to help member advocates deliver faster, more personalized responses to health benefits and eligibility questions, the release said.
Humana stock plummeted 21% on January 27. Humana is a "pure play" on Medicare Advantage—around 85% of their operations.
HUM teams up with Atlas Oncology to make a cancer care model available for its eligible MA members in TN and MS starting in 2026.
HUM sits at a crossroads as Medicare Advantage pressures cap near-term upside, but resilience versus peers argues for patience, not panic.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The U.S. Defense Department on Wednesday said it was exercising an option to award Humana a $7.3 billion deal for health care and administrative support services.
Humana (HUM) reported earnings 30 days ago. What's next for the stock?